CCL4 Protein

Produktnummer ABIN7668467

Dieses Recombinant CCL4-Protein wird in Escherichia coli (E. coli) exprimiert.

Kurzübersicht für CCL4 Protein (ABIN7668467)

Target: CCL4 (Chemokine (C-C Motif) Ligand 4 (CCL4))

Protein-Typ: Recombinant

Biologische Aktivität: Active

Spezies: Human

Quelle: Escherichia coli (E. coli)

Applikation: Cell Culture (CC)

Reinheit: > 98 %

Produktdetails

Verwendungszweck: Recombinant Human CCL4 protein(His Tag)

Sequenz: Ala 24-Asn 92

Sterilität: 0.2 μm filtered

Endotoxin-Niveau: < 0.1 EU per μg of the protein as determined by the LAL method.

Biological Activity Comment: Measure by its ability to chemoattract BaF3 cells transfected with human CCR5.The ED₅₀ for this effect is <10 ng/mL.

Anwendungsinformationen

Applikationshinweise: Optimal working dilution should be determined by the investigator.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Lyophilized

Buffer: Lyophilized from sterile 50 mM Tris, 150 mM NaCl, pH 8.5.
Normally 5 % - 8 % trehalose, mannitol and 0.01 % Tween 80 are added as protectants before lyophilization.

Lagerung: 4 °C,-20 °C,-80 °C

Informationen zur Lagerung: Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80°C. Reconstituted protein solution can be stored at 4-8°C for 2-7 days. Aliquots of reconstituted samples are stable at < -20°C for 3 months.

Haltbarkeit: 12 months

Antigendetails

Target: CCL4 (Chemokine (C-C Motif) Ligand 4 (CCL4))

Andere Bezeichnung: CCL4

Hintergrund: CCL4 (C-C chemokine ligand 4), is a macrophage inflammatory protein with a chief effect in inflammation and immune-regulation, and was documented in cancer progression by promoting instability in the tumor environment. The inflammatory chemokine (C-C motif) ligand 4 (CCL4) plays an important role in the pathogenesis and progression of cancer. In particular, higher serum CCL4 levels in patients with oral squamous cell carcinoma (OSCC) are associated with a more advanced stage of disease. CCL4 may be a new molecular therapeutic target for inhibition of lymphangiogenesis and metastasis in OSCC. CCL3 and CCL4 loci may be marker SNPs for risk of HCV treatment outcome. CCL4 can enhance the recruitment of preosteoclasts to bone in the early stage, and the reduction of CCR5 promotes osteoclastogenesis when RANKL is prevalent.,ACT-2,MIP-1b: Macrophage Inflammatory Protein-1β

Molekulargewicht:

calculated_mw: 7.8 kDa

observed_mw: 11 kDa

UniProt: P13236